Radiological characteristics for guiding intra-arterial therapy in intermediate-stage hepatocellular carcinoma

放射学特征指导中晚期肝细胞癌的动脉内治疗

阅读:2

Abstract

BACKGROUND: To evaluate and contrast the efficacy and safety of trans-arterial chemoembolization (TACE) versus hepatic arterial infusion chemotherapy (HAIC) for intermediate-stage hepatocellular carcinoma (HCC) based on varying radiologic patterns. METHODS: A retrospective study identified 3,060 consecutive patients with intermediate-stage HCC who underwent initial TACE or HAIC between January 2009 and December 2022. HCC radiological features were categorized into pseudo-capsulated, pseudocapsule breakthrough, confluent multinodular, and infiltrative types. The propensity score matching (PSM) method was employed to minimize selection bias. The progression-free survival (PFS) was compared using the Kaplan-Meier method with the log-rank test. Independent prognostic factors were assessed using a forward stepwise Cox regression model in multivariable analyses. RESULTS: After propensity score matching, each group in the infiltrative HCC cohort included 237 patients, while the non-infiltrative HCC cohort comprised 262 patients per group. Notably, radiologic patterns were shown with statistical significance in three groups with different tumor burden (P < 0.001). Pseudo-capsulated type was dominant (55.6%) in < 6 cohorts, and infiltrative type was dominant (49.5%) in > 12 cohorts. A higher PFS was observed in the HAIC group compared to the TACE group in the infiltrative HCC cohort (P < 0.001), but comparable PFS was found between the two groups in the non-infiltrative HCC cohort (P = 0.532). In the multivariate analysis, both tumor burden and radiologic morphology showed significant associations with PFS. CONCLUSIONS: HAIC showed favorable outcomes in infiltrative HCC and might warrant further consideration in treatment planning.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。